Time to Take the Lead – Practical Utilization of SGLT2 Inhibitors
Published: 07 September 2020
12m 25sPart 4 Case Discussion
This educational symposium first broadcast at the ESC Congress 2020 discusses how SGLT2 inhibitors should be utilised by cardiologists in everyday practice
- Understand current guidelines and utilisation of SGLT2i
- Describe the potential mechanism of benefit of SGLT2i
- Initiate and manage SGLT2i in appropriate patients
More from this programme
Introduction, and No Permission Needed – Cardiology Guidelines + Prescribing Practice
SGLT2i are Cardiovascular Drugs
Cardiologists Taking the Lead – How Can We Use SGLT2 Inhibitors in Our Clinical Practice?
A Follow-up Discussion to the ESC 2020 Session
Director of the Heart Failure and Heart Transplant Clinics
Dr Shelley Zieroth is Professor at the College of Medicine, Max Rady Faculty of Health Sciences, University of Manitoba, as well as Director of the Heart Failure and Heart Transplant Clinics at St. Boniface Hospital in Winnipeg, CA.
She is also Head of the Medical Heart Failure Program for Cardiac Sciences Manitoba. She is involved in several heart failure clinical trials as a PI, National Lead or Executive Committee member. She is the Immediate Past President of the Canadian Heart Failure Society and Co-Chair of the Canadian Cardiovascular Society Heart Failure Guidelines. She serves as Co-Chair of Canada’s largest annual heart failure meeting, HF Update and serves as Scientific Planning Committee Chair for the Canadian Cardiovascular Congress hosted by the Canadian Cardiovascular Society. She is currently President-elect of the Federation of Medical Women of Canada.